Friday, the FDA lifted the clinical hold on Biomea Fusion, Inc.’s (NASDAQ:BMEA) ongoing Phase 1/2 clinical trials of the ...

The FDA placed a full clinical hold on two diabetes trials for Biomea’s menin inhibitor after reports of liver toxicity.

Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Biomea Fusion (BMEA – Research Report). The associated ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Biomea Fusion (BMEA – Research Report), with a ...

Biomea Fusion, Inc. BMEA shares jumped 15.5% to $11.05. Biomea Fusion disclosed that the FDA lifted its clinical hold on ...

Biomea (BMEA) has received two analyst upgrades along with bullish comments from other firms following news the FDA has lifted a clinical hold on a study of its drug BMF-219.

On Thursday, Biomea Fusion Inc (BMEA) stock saw a modest uptick, ending the day at $9.57 which represents a slight increase of $0.80 or 9.12% from the prior close of $8.77. The stock opened at $8.98 ...

Biomea Fusion, Inc. ("Biomea" or the "Company") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing ...

The drug BMF-219 works by increasing, preserving and reactivating patients’ own healthy insulin-producing cells. Read more at ...

Biomea Fusion has escaped from the full clinical hold imposed by the FDA. | Biomea Fusion has escaped from the full clinical hold imposed by the FDA. After reviewing the data, the regulator has ...

REDWOOD CITY, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent ...

Stocks today are mixed, with the Dow Jones Industrials climbing to a new record high. Today’s US personal spending and income ...